VETTORI, Serena
 Distribuzione geografica
Continente #
EU - Europa 4.562
NA - Nord America 2.592
AS - Asia 1.887
SA - Sud America 421
Continente sconosciuto - Info sul continente non disponibili 191
AF - Africa 31
OC - Oceania 1
Totale 9.685
Nazione #
RU - Federazione Russa 2.741
US - Stati Uniti d'America 2.501
SG - Singapore 738
IE - Irlanda 492
CN - Cina 378
BR - Brasile 360
HK - Hong Kong 300
IT - Italia 266
UA - Ucraina 214
GB - Regno Unito 209
DE - Germania 206
VN - Vietnam 202
FR - Francia 181
TR - Turchia 77
GR - Grecia 67
FI - Finlandia 62
KR - Corea 61
SE - Svezia 50
CA - Canada 49
IN - India 36
BE - Belgio 30
AR - Argentina 28
BD - Bangladesh 11
EC - Ecuador 11
ID - Indonesia 11
IQ - Iraq 11
JP - Giappone 11
MX - Messico 11
AT - Austria 9
ZA - Sudafrica 9
CO - Colombia 8
PK - Pakistan 8
NL - Olanda 7
TT - Trinidad e Tobago 7
UZ - Uzbekistan 7
EG - Egitto 6
KE - Kenya 6
PE - Perù 6
NI - Nicaragua 5
CH - Svizzera 4
EU - Europa 4
HR - Croazia 4
PH - Filippine 4
TH - Thailandia 4
TN - Tunisia 4
VE - Venezuela 4
AZ - Azerbaigian 3
CR - Costa Rica 3
ES - Italia 3
HN - Honduras 3
HU - Ungheria 3
KZ - Kazakistan 3
PL - Polonia 3
SA - Arabia Saudita 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
BB - Barbados 2
BW - Botswana 2
BY - Bielorussia 2
CL - Cile 2
CU - Cuba 2
CZ - Repubblica Ceca 2
GT - Guatemala 2
IL - Israele 2
IR - Iran 2
JM - Giamaica 2
JO - Giordania 2
LT - Lituania 2
MA - Marocco 2
NP - Nepal 2
SV - El Salvador 2
BN - Brunei Darussalam 1
BS - Bahamas 1
CW - ???statistics.table.value.countryCode.CW??? 1
DK - Danimarca 1
DZ - Algeria 1
GE - Georgia 1
KG - Kirghizistan 1
KI - Kiribati 1
KW - Kuwait 1
LB - Libano 1
LK - Sri Lanka 1
MN - Mongolia 1
MY - Malesia 1
OM - Oman 1
PA - Panama 1
PR - Porto Rico 1
PT - Portogallo 1
PY - Paraguay 1
RO - Romania 1
SN - Senegal 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 9.500
Città #
Moscow 982
Dublin 491
Jacksonville 361
Santa Clara 353
Singapore 294
Hong Kong 292
San Jose 225
Ashburn 191
Council Bluffs 151
Chandler 124
Beijing 93
Bremen 77
Princeton 77
Ho Chi Minh City 74
Ann Arbor 73
Seoul 61
Medford 60
Roxbury 55
Hanoi 42
Wilmington 38
Milan 35
Woodbridge 35
Hefei 33
Brussels 30
Caserta 28
Des Moines 28
Ottawa 25
Boardman 23
Cambridge 21
Bengaluru 20
Munich 20
San Mateo 20
New York 19
São Paulo 19
Dallas 18
Haiphong 18
Los Angeles 16
Miano 16
Frankfurt am Main 15
Mountain View 15
Rio de Janeiro 14
Napoli 13
The Dalles 12
Brasília 11
Guangzhou 10
Helsinki 10
Biên Hòa 9
Curitiba 9
Da Nang 9
Falls Church 9
Chicago 8
Düsseldorf 8
Jinan 8
Nanjing 8
Nuremberg 8
Auburn Hills 7
Belo Horizonte 7
Fiano Romano 7
Orem 7
Tokyo 7
Atlanta 6
Changsha 6
Dong Ket 6
Falkenstein 6
Fortaleza 6
Guayaquil 6
Hanover 6
Johannesburg 6
Nairobi 6
Naples 6
San Francisco 6
Tashkent 6
Baghdad 5
Brooklyn 5
Dhaka 5
Houston 5
London 5
Maceió 5
Managua 5
Montréal 5
North Bergen 5
Toronto 5
Cairo 4
Hebei 4
João Pessoa 4
Lagoa Santa 4
Lima 4
Ningbo 4
Norwalk 4
Piracicaba 4
Porto Alegre 4
Recife 4
Roubaix 4
Seattle 4
São Bernardo do Campo 4
Turin 4
Amsterdam 3
Ankara 3
Baku 3
Bauru 3
Totale 4.939
Nome #
Clinical and subclinical atherosclerosis in systemic sclerosis: consequences of previous corticosteroid treatment. 210
Association between a stromal cell-derived factor 1 (SDF-1/CXCL12) gene polymorphism and microvascular disease in systemic sclerosis 193
CLINICAL AND SUBCLINICAL ATHEROSCLEROSIS IN SYSTEMIC SCLEROSIS (SSC) PATIENTS 184
Clinical correlates of human leukocyte antigen-G (HLA-G) in systemic sclerosis. 175
Early systemic sclerosis: Analysis of the disease course in patients with marker autoantibody or capillaroscopic positivity or both. 166
CXCL4 in undifferentiated connective tissue disease at risk for systemic sclerosis (SSc) (previously referred to as very early SSc) 166
ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis-a EUSTAR analysis. 163
Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) survey 162
Early Systemic Sclerosis: Marker Autoantibody Positive Patients Have A Faster Pace Of The Disease. 161
Early systemic sclerosis: marker autoantibodies and videocapillaroscopy patterns are each associated with distinct clinical, functional and cellular activation markers. 156
[Survival and death causes in 251 systemic sclerosis patients from a single Italian center]. 150
Polymorphism of immunoglobulin enhancer element HS1,2A: allele *2 associates with systemic sclerosis. Comparison with HLA-DR and DQ allele frequency 145
Downregulation of miR-193b in systemic sclerosis regulates the proliferative vasculopathy by urokinase-type plasminogen activator expression 145
[Hypocomplementemia in systemic sclerosis]. 143
Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features 142
CROSS-SECTIONAL EVALUATION OF CHEMOKINE PROFILE IN EARLY AND DEFINITE SYSTEMIC SCLEROSIS 142
Clinical determinants of elevated systolic pulmonary artery pressure measured by transthoracic Doppler echocardiography in early systemic sclerosis 140
CARDIAC BLOCKS IN SYSTEMIC SCLEROSIS: PREVALENCE AND ASSOCIATED FEATURES IN THE EUSTAR COHORT 138
Differences associated with age at onset in early systemic sclerosis patients: a report from the EULAR Scleroderma Trials and Research Group (EUSTAR) database 138
The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: Derivation and validation of a preliminarily revised EUSTAR activity index 137
Anti-carbamylated protein antibodies and skin involvement in patients with systemic sclerosis: An intriguing association 137
A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study 134
Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis 133
EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research 132
Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): Efficacy of maintenance immunosuppression in responders and non-responders. 131
Tissue Doppler imaging in systemic sclerosis: A 3-year longitudinal study. 129
Non-Hodgkin's lymphoma in systemic sclerosis: case and literature review 129
European Scleroderma Study Group (ESCSG) Activity Index is correlated to quality of life measures both at admission and overtime 127
Mapping and predicting mortality from systemic sclerosis 127
High IL-17E and Low IL-17C Dermal Expression Identifies a Fibrosis-Specific Motif Common to Morphea and Systemic Sclerosis. 126
Quality of life as measured by the short-form 36 (SF-36) questionnaire in patients with early systemic sclerosis and undifferentiated connective tissue disease. 126
Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy 125
Early Systemic Sclerosis: Serum Profiling of Factors Involved in Endothelial, T-cell, and Fibroblast Interplay is Marked by Elevated Interleukin-33 Levels. 123
T-Cell Proapoptotic and Antifibrotic Activity Against Autologous Skin Fibroblasts in vitro Is Associated With IL-17A Axis Upregulation in Systemic Sclerosis 119
Peripheral blood mononuclear cells (PBMCs) of systemic sclerosis patients induce apoptosis in cocultured autologous fibroblasts and up-regulate HLA-DR and FASL 118
SAT0181 CXCL4 Is Not A Biomarker in Rheumatoid Arthritis Patients Treated with Abatacept and Tocilizumab 118
Fulminant Myocarditis Unmasking Adult-Onset Still's Disease and Desmoplakin Truncation 115
Right atrial morphology and function in patients with systemic sclerosis compared to healthy controls: a two-dimensional strain study 114
Functional changes in scleroderma fibroblasts co-cultured with autologous peripheral blood mononuclear cells (PBMCS) 113
Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: A EUSTAR analysis 113
SURNATANTS FROM SYSTEMIC SCLEROSIS PBMCS CO-CULTURED WITH AUTOLOGOUS FIBROBLASTS DISPLAY HIGH LEVELS OF PRO-FIBROTIC CYTOKINES 113
Early systemic sclerosis: short –term disease evolution and factors predidting the development of new manifestations of organ involvement 113
The Concept of Early Systemic Sclerosis Following 2013 ACR\EULAR Criteria for the Classification of Systemic Sclerosis. 111
Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database 110
International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management 110
Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: A prospective cohort study 110
Peripheral T cells from patients with early systemic sclerosis kill autologous fibroblasts in co-culture: is T-cell response aimed to play a protective role? 109
Serum CXCL4 Increase in Patients with Undifferentiated Connective Tissue Disease at Risk for Systemic Sclerosis Is Associated with Anti-Scl70 Antibodies and ICAM-1, a Marker of Endothelial Activation 109
Use of vasoactive/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher study 109
Functional disability and its predictors in systemic sclerosis: a study from the DeSScipher project within the EUSTAR group 108
The cumulative number of micro-haemorrhages and micro-thromboses in nailfold videocapillaroscopy is a good indicator of disease activity in systemic sclerosis: A validation study of the NEMO score 108
Serum CXCL4 increase in primary Sjögren’s syndrome characterizes patients with microvascular involvement and reduced salivary gland infiltration and lymph node involvement 107
Role of microRNAs in fibrosis 106
Subspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease 106
Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database 105
The β-fibrinogen -455 G>A gene polymorphism is associated with peripheral vascular injury in systemic sclerosis patients 105
Outcome of a glucocorticoid discontinuation regimen in patients with inactive systemic sclerosis 105
Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: A longitudinal EUSTAR study 105
FRI0446 Severe Heart Disease in Systemic Sclerosis: Prevalence, Risk Factors and Current Treatment. A Eustar-Desscipher Study 103
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease 103
Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular manifestations in systemic sclerosis 101
Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis 101
Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database 99
Longitudinal analysis of quality of life in patients with undifferentiated connective tissue diseases 99
N-terminal pro-brain natriuretic peptide is a strong predictor of mortality in systemic sclerosis 99
FRI0522 Peripheral Blood Mononuclear Cells Co-Cultured with Autologous Skin Fibroblasts Up-Regulate IL-17A and Play Anti-Fibrotic Effects in Systemic Sclerosis 96
Gender differences in early systemic sclerosis patients: a report from the EULAR scleroderma trials and research group (EUSTAR) database 96
Phenotypes determined by cluster analysis and their survival in the prospective EUSTAR cohort of patients with systemic sclerosis 96
Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database 95
Performance of a new quantitative computed tomography index for interstitial lung disease assessment in systemic sclerosis 94
Peripheral Blood Mononuclear Cells Co-Cultured With Autologous Skin Fibroblasts Up-Regulate IL-17A and Play Anti-Fibrotic Effects In Systemic Sclerosis. 93
Esophageal high-resolution impedance manometry alterations in asymptomatic patients with systemic sclerosis: prevalence, associations with disease features, and prognostic value 92
Identification of a New Set of Activity Criteria for Systemic Sclerosis. Preliminary Report 91
IL-22 capacitates dermal fibroblast responses to TNF in scleroderma 90
Hemodynamic changes after acute fluid loading in patients with systemic sclerosis without pulmonary hypertension 90
Hypocomplementemia in Systemic sclerosis - Author reply 89
Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort 86
MiRs in RA: possible biomarkers and therapeutic targets 84
Progression, Management, and Outcome of Aortic Valve Stenosis in Systemic Sclerosis: A Case Series 82
What have multicentre registries across the world taught us about the disease features of systemic sclerosis? 75
Diffuse Cutaneous Systemic Sclerosis Complicated by Serum Amyloid A Protein Cardiac Amyloidosis and Cardiogenic Shock 37
Totale 9.685
Categoria #
all - tutte 35.354
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.354


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022451 0 0 0 25 175 6 14 7 14 32 39 139
2022/2023809 99 56 5 29 103 38 3 28 413 7 8 20
2023/2024326 27 15 8 23 121 11 3 9 1 23 26 59
2024/20251.209 6 8 0 15 187 199 238 79 125 230 67 55
2025/20264.445 145 145 237 283 405 2.572 227 98 145 110 56 22
2026/2027756 26 106 318 306 0 0 0 0 0 0 0 0
Totale 9.685